Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PS anyone notice good-pal is gone for good? or did you all have him on ignore anyways?
The board is much more civil and much less cluttered by garbage. I wish RB and Yahoo kept a tight ship like they do here at Ihub.
let's hope you guys are right and Dr. Sell contributes greatly in the publishing department. FDA approval is worthless if the medical community is not aware of your product.
RMZ: I cannot reply via PM because I'm not a premium member. I have to say right off the bat that
1) I don't touch HIV/AIDS stocks
2) I don't usually touch penny stocks (BOCX is an exception)
Sorry I can't be of more help...good luck with it.
longterm: Yes...I know the feeling of being in a stock way too early. You watch the impatient investors come and go on the message boards, only to kick themselves after the big pop.
Development stage medical stocks are different from brick and mortar stocks in the sense that the gains are concentrated over the course of a few trading days around pivotal events like trial data and FDA approval. If you've ever been in a stock that has rocketed hundreds of % in a day, you know it's worth the long wait. You watch all the momentum traders try to chase what's left of the breakout, but meanwhile you were the one holding shares the night before the monster gap.
longterm: BUT, I've never been more excited about the company's prospects. it's these long, quiet periods with biotechs that flush out the impatient amateurs and set up the stock for the next big move.
yawn
zolax: NDA's are a b**tch.
+20% on 7.5k? LOL.
IMO the market maker bought the 350k shares and "paper" as we say sold it. we'll see a Form 4 soon if it was a d/o that sold.
great-grandma: I have been quiet because there has been nothing interesting out of this stock for a long time. But there will be. As far as the downward trickle...development stage biotech's are all the same. They spike at pivotal moments in the development stage like major partnership, data release, FDA approval, etc...and they sell-off during these long quiet periods.
My only hope is that we are off the pink sheets when the next pivotal event strikes. 2006 will be a good year for us.
My only concern with the stock at this point is the need to continually raise cash via equity sale at these low prices.
shag it is becoming sort of ridiculous at this point. if they were not a fully reporting pink i could understand (kind of), but while on the pinks they have been paying considerable money to a reputable accounting firm in order to be fully reporting, SOX compliant, etc. is it just management ineptitude or what?
Something tells me good-pal finally got TOS'd, as I can't remember the last time he went 3 days without posting.
Up 16% on 1700 shares. I am totally disregarding the price movement until we start seeing 100k+ days again.
I'm cracking up...the Q3 10-Q was filed on November 14th, nitwits. The "news" that these trolls are referring to was just the Edgar's circulation of the 10-q data (which is always delayed from the SEC filing).
It just shows you the level of sophistication we are dealing with here.
See here:
hxxp://yahoo.brand.edgar-online.com/default.aspx?cik=1092562
shun + report TOS violations for me
good idea foam...i'm in.
guys...here's a news flash. any new and "material" information that was said at ISOBM would have had to be disseminated already per Regulation FD. so...as i said in the morning, those of you expecting a weeks old recording of the ISOBM presentation to cause a spike in the SP have got to be kidding. whether we're on the pink sheets or the nasdaq, an old recording would not move a stock because any material disclosures from the presentation would already have been filed as an 8-k or otherwise disseminated to shareholders...this is a public company!
foam: thanks a lot.
that update will not "skyrocket" our share price...give me a break man.
foam: can you give me a rough idea of what was asked in the Q&A part? I couldn't understand a WORD said.
half-full: the bph trial is good evidence that recaf is not simply picking up on inflammation and other "stirrings" from the prostate -- it's picking up on the malignancy itself.
my understanding is that telomerase -- GERN and Boehringer-Mann's much hyped marker -- got scrapped for the most part as a (universal) diagnostic tool because it was found to be expressed under a variety of ailments and conditions...not just in cancer patients. that is one of the big risks with RECAF, IMO, but it is very encouraging to see that the company has already thrown some curve balls at the data. and it's not only the BPH/Prostate Cancer head to head...there was also a trial i saw for the first time of BBS/Breast Cancer.
after watching the presentation, i have realized that bocx has tested RECAF on a much larger and diverse sample than i previously thought. also, the extraordinary p-values, especially on some of the larger trials where n > 300, are very encouraging.
lastly, remember my posts from a few weeks ago regarding the cutoff curve for sensitivity/specificity...and how RECAF hadn't just achieved good accuracy -- it was the phenomenal cutoff curve that really tells the story. well, the presentation has some great material evidencing the cutoff curves (called "ROC curves" in the presentation) for several other trials, not just the lung cancer study which was previously published on BOCX's site. remarkable stuff...check you guys later.
holy cow and did you guys know about the BPH/Prostate study where n > 100? i missed that one (assuming it has been presented before). getting through BPH misdiagnosis is a huge potential risk with our prostate cancer indication, so that data is very very important.
you guys seeing the p-values on the data presented? also, some of these prelim trials were larger than i thought. i'm loving this presentation -- wow! you couple that with the fact abbott has bought in, and i think we have a recipe for a potentially astounding breakout at some point.
man i can't understand a word he's saying.
watching the presentation...i'm interesting in learning more about this german group. the data is impressive.
good-pal: you obviously didn't understand the offering filing.
10-Q just filed today...some random notes:
- cash position still pretty decent...we're sitting with around $350k of cash (and another $350k in PKTX stock). that might sound pathetic but it is a lot of cash for this company to have on hand historically speaking.
- they're doing the offerings at much higher prices...they sold around 100k shares this quarter, most of it at $1 and some at .75. That is a big difference from the offerings at $.10/.20/.30 we were seeing that diluted the s**t out of us but raised barely any cash. they also gave away 50k restricted shares at $1, presumably to j.p turner or the guys before them (i've lost track at this point)
other than that not much new.
a1: spare me...you have no idea what we've been through with good-pal/goodman/Kywaiti-Guy between RB and this board.
erthang: click on one of his posts, then look for the blue bar at the bottom. one of the links on the blue bar is "Report TOS Violation"
...after reading the investorshub TOS i have no doubt he is violating it, but my guess is that a few people need to report him to get the admins' attention. who knows though.
good-pal = a spoiled Kuwaiti boy.
please report TOS violation on good-pal...I think his posts qualify as SPAM but the admins will have to decide that.
good-pal weren't you leaving? what happened to that?
i'm with headache...Good-pal: please keep selling shares and don't forget to keep telegraphing your intentions ahead of time. best of luck.
erthang please leave it alone he said he was leaving...that is the best news we've gotten since the abbott deal!!!!
bye bye good-pal.
Guys if good-pal is bothering you feel free to use the "report TOS violation" feature of investorshub -- I know I have. :)
good-pal: we discussed that ad nauseaum on the RB board so yes, I know what you're talking about. the point is that despite the value it's recorded it, it would be a worthless asset to claim at that point (ie; even if it was recorded as $10 mil).
by the way, numbskull, it had nothing to do with RECAF and everything to do to sarbanes-oxley technicalities.
sheeesh you are just so clueless.
good-pal: rather than playing the game of trying to guess sensitivity/specificity and trying to gauge abbott's expectations from one general sentence in the p.r, look at it like this. there are two big pieces of evidence that abbott views RECAF as a VERY REAL COMMERCIAL OPPORTUNITY:
1) in my estimation they have spent around $1 mil already on RECAF between due diligence (G*D knows there was a lot considering BOCX's messy past), legal, blind sample testing (expensive!), ARCHITECT integration, and the $250k upfront. they are investing time, money and resources!
2) if you look through Abbott's p.r archive they do not sign a lot of these licensing deals. that alone says a hell of a lot to the crowd that thinks abbott goes around signing ldm deals with all these dozens of cancer marker companies touting their goods (ie and bocx is just lost in the crowd)
good-pal: lol...the IP on the balance sheet is an intangible asset so there is nothing to claim there, especially considering it would be worthless under the circumstances we're talking about (ie data comes in very sub par)
there is NOTHING on the balance sheet that would entice any securities lawyer to take the case on consignment. it just wouldn't happen.
NOW...in the event that we crashed because of bad data i would have a considerable loss -- enough to motivate me to pay out of pocket to my firm to see if there was any corporate looting on the part of the d/o's (i've asked already, and my firm would not take a case like that out of pocket because it's too much of a wild guess). if evidence of looting was found, that would be criminal behavior and the d/o's would not be protected by the limited liability statutes.
"corporate looting" in this case means one thing, and it is not a huge deal to subpoena documents and check it out. basically a corporate d/o or related party would hold an account at one of the firms making a market in this stock or even a b/d capable of shorting this stock in the open market. the d/o or related party would short shares in the open market via this account, and then issue options to himself or a related party with an extremely low excercise price. this is perhaps the last remaining use (an a malicious one at that) of an old trading tactic known as "shorting against the box." the d/o's profit would be the SHORTING PRICE minus the STRIKE PRICE of his options. he would merely deliver the shares acquired upon exercise to the MM or B/D that is holding his short shares -- the delivered shares would serve to "cover" his open market short.
i will raise hell for the d/o's if they are engaged in this sort of activity -- believe me. they will return large sums to the company and go to jail.
but i do not believe that they are involved in that, and i don't think abbott would get in bed with an outright scam like that.
bingo rajacat